OGEN .625
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OGEN .625 (OGEN .625).
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
| Metabolism | Primarily metabolized in the liver via CYP3A4; undergoes first-pass metabolism including sulfation and glucuronidation. Estropipate is hydrolyzed to estradiol and then metabolized. |
| Excretion | Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation. |
| Half-life | Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing. |
| Protein binding | ~50-80% bound to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Estrone: ~1-2 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~30-50% due to first-pass metabolism; micronized formulation enhances absorption. |
| Onset of Action | Oral: symptomatic relief of vasomotor symptoms begins within 2-4 weeks. |
| Duration of Action | Oral: 24 hours with once-daily dosing; steady-state estrogen effects maintained with continuous therapy. |
0.625 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; insufficient data for GFR <30 mL/min, use with caution |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated |
| Pediatric use | Not indicated for use in pediatric patients |
| Geriatric use | Use lowest effective dose; monitor for thromboembolic events and malignant neoplasms; no specific dose adjustment recommended |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OGEN .625 (OGEN .625).
| Breastfeeding | Estropipate (ogen) is excreted into human breast milk. The milk-to-plasma ratio (M/P ratio) is not established in published literature. Exogenous estrogens may reduce milk production and quality, particularly in early postpartum. Use during breastfeeding is generally not recommended due to potential adverse effects on the infant, including jaundice and long-term effects on reproductive development. Alternative therapies should be considered. |
| Teratogenic Risk | First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use is contraindicated in pregnancy. Second and third trimesters: Exposure may increase risk of fetal urogenital tract abnormalities, and estrogens have been linked to an elevated risk of vaginal clear cell adenocarcinoma in female offspring. Overall, use is contraindicated throughout pregnancy due to known fetal risks. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Also, estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported with estrogen-alone therapy.
| Serious Effects |
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of venous thromboembolism; active or recent arterial thromboembolic disease (e.g., stroke, MI); liver dysfunction or disease; known hypersensitivity to estrogens; known protein C, protein S, or antithrombin deficiency; and pregnancy.
| Precautions | Increased risk of endometrial cancer; cardiovascular disorders (MI, stroke, VTE); probable dementia; breast cancer; gallbladder disease; hypercalcemia; fluid retention; visual abnormalities; hereditary angioedema; exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas; hypothyroidism; elevated triglycerides; and hypersensitivity reactions. |
Loading safety data…
| Fetal Monitoring | For women inadvertently exposed during pregnancy: Fetal ultrasound for genital anomalies, urogenital tract assessment. For pregnant patients, monitor for signs of fetal distress via nonstress test and biophysical profile as clinically indicated. Also monitor maternal blood pressure, weight gain, and blood glucose levels due to potential estrogenic effects on metabolic parameters. |
| Fertility Effects | Estropipate can inhibit ovulation and disrupt menstrual cycle regularity, potentially impairing fertility during use. Discontinuation of therapy restores normal cyclic function and fertility. Use as a component of menopausal hormone therapy does not enhance fertility; instead, it suppresses gonadotropin secretion and may delay conception. |